StockNews.com Initiates Coverage on Affimed (NASDAQ:AFMD)

Equities researchers at StockNews.com began coverage on shares of Affimed (NASDAQ:AFMD) in a research note issued on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

AFMD has been the topic of a number of other research reports. Truist Financial lowered their price objective on Affimed from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Friday, August 11th. Cantor Fitzgerald reissued an “overweight” rating and set a $7.00 price objective on shares of Affimed in a report on Monday, September 25th. Berenberg Bank reissued a “buy” rating and set a $6.00 price objective on shares of Affimed in a report on Tuesday, August 8th. Finally, HC Wainwright reissued a “buy” rating and set a $5.00 price objective on shares of Affimed in a report on Friday, August 11th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $5.50.

Affimed Stock Up 4.2 %

AFMD opened at $0.36 on Friday. Affimed has a fifty-two week low of $0.22 and a fifty-two week high of $2.55. The business has a 50-day moving average of $0.45 and a 200-day moving average of $0.62. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.05 and a quick ratio of 5.03. The company has a market capitalization of $54.48 million, a PE ratio of -0.47 and a beta of 2.08.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings results on Thursday, August 10th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.22). Affimed had a negative return on equity of 79.96% and a negative net margin of 357.49%. The company had revenue of $1.51 million during the quarter, compared to the consensus estimate of $4.83 million. Equities research analysts forecast that Affimed will post -0.84 EPS for the current fiscal year.

Institutional Trading of Affimed

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AFMD. XTX Topco Ltd acquired a new stake in Affimed in the 1st quarter valued at approximately $27,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Affimed during the 1st quarter worth approximately $28,000. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Affimed during the 2nd quarter worth approximately $31,000. UBS Group AG grew its holdings in shares of Affimed by 42.2% during the 1st quarter. UBS Group AG now owns 47,073 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 13,979 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Affimed by 30.9% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 13,570 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 3,202 shares in the last quarter. Institutional investors and hedge funds own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.